Quotables
"What, sir, would you make a ship sail against the wind and currents by lighting a bonfire under her deck? I pray you, excuse me, I have not the time to listen to such nonsense."
Napoleon Bonaparte ; When told of the Robert Fulton steamboat
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 6013264 | Vaccine Stable and effective multivalent vaccine compositions comprising Hepatitis B surface antigen (HBsAg) are described wherein the HBsAg component is stable for one week at 37° C. and is highly immunogenic, for example when the vaccine is administered to inf... | 01/11/2000 |
| 5972346 | Hepatitis B vaccine A novel vaccine formulation is provided, comprising a hepatitis B component, particularly hepatitis B surface antigen, in combination with aluminum phosphate and 3-O-acylated monophosphoryl lipid A.... | 10/26/1999 |
| 5879685 | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them Immunostimulating reconstituted influenza virosomes (IRIVs) are provided wherein an antigen or a combination of antigens are incorporated into a virosome further containing a mixture of phospholipids, an essentially reconstituted functional virus envelope... | 03/09/1999 |
| 5837260 | Chimeric hepatitis A vaccine A full-length cDNA copy of an attenuated, cell culture-adapted hepatitis-A virus genome has been constructed. The HAV cDNA when inserted, without the oligo (dG) oligo (dC) tails, into an RNA transcription vector yielded a plasmid designated pHAV/7. Transf... | 11/17/1998 |
| 5807757 | Preparation of ionically cross-linked polyphosphazene microspheresy by coacervation A method is provided for preparing polyphosphazene microspheres wherein the polyphosphazene microspheres are produced by coacervation. A solution containing a polyphosphazene is admixed with a solution containing a salt of a monovalent ion such as a salt ... | 09/15/1998 |
| 5776468 | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A Novel vaccine compositions comprising small particles of 3-O-deacylated monophosphoryl lipid A are provided. In particular the particle size is below 120 nm. Such vaccine compositions have superior immunological properties.... | 07/07/1998 |
| 5766603 | Cell culture of hepatitis A virus Hepatitis A virus is attenuated in virulence by in vitro passage in susceptible cell cultures, without prior passage in a subhuman primate. This process results in a live, attenuated hepatitis A virus vaccine suitable for human disease prevention.... | 06/16/1998 |
| 5766906 | Hepatitis A virus deletion mutants and vaccine formulations containing the same Disclosed are live hepatitis A virus deletion mutants having a deletion mutation in the 5' nontranslated region of the viral genome. The deletion mutation may be selected from the group consisting of (a) pY1 deletion mutations that cause the virus to reta... | 06/16/1998 |
| 5731187 | Process for preparing hepatitis A (HAV) antigens and vaccines Process for preparing hepatitis A (HAV) antigens and vaccines. The HAV virus is multiplied on competent cells, the infected cells are lysed, the supernatant is recovered and the purification is carried out by a chromatographic procedure on an anion-exchange su... | 03/24/1998 |
| 5719049 | Process for purifying hepatitis A virus (HAV), virus thus purified and vaccine compositions containing it A process is described for the purification or the hepatitis A virus, which allows one to obtain with good yields a pure product, in which organic material collected by centrifugation after lysis or the culture cells is submitted to gel filtration and suc... | 02/17/1998 |
| 5609871 | Oral administration of therapeutic proteins for treatment of infectious disease An orally administrable therapeutic protein is provided by combining the therapeutic protein with a stabilizing agent in an aqueous solution. The solution is coated onto nonpareils and microencapsulated with a water emulsifiable enteric coating compositio... | 03/11/1997 |
| 5607851 | Process for purifying hepatitis a virus (HAV), and vaccine compositions containing hepatitis a virus A process is described for the purification of the hepatitis A virus, which allows one to obtain with good yields a pure product, in which organic material collected by centrifugation after lysis of the culture cells is submitted to gel filtration and suc... | 03/04/1997 |
| 5605692 | Expression of structural (P1) region of 1 hepatitis A virus by vaccinia in cell culture for use in vaccines An isolated polypeptide comprising a substantially antigenic part of at least one hepatitis A virus epitope, the polypeptide being free from infectious material. The polypeptide is the expression product of a DNA molecule which has been incorporated into ... | 02/25/1997 |
| 5565203 | Hepatitis A virus in a reconstituted influenza virosome and use as a vaccine Disclosed are immunostimulating reconstituted influenza virosomes (IRIVs) comprising reconstituted functional virus envelopes containing an inactivated hepatitis A virus and an influenza hemagglutinin protein (HA) or a peptide with the amino terminal 21 a... | 10/15/1996 |
| 5549896 | Hepatitis a virus strain, method for the isolation of new hepatitis a virus strains and hepatitis a vaccines The invention relates to hepatitis A viruses (HAVs) having a serotype displaying the immunological characteristics of the HAV strain RG-SB XA112 (CNCM I-1080). In particular, the invention relates to the new hepatitis A virus strain RG-SB XA112 (CNCM I-10... | 08/27/1996 |
| 5506129 | Virus production A process for the propagation of hepatitis A virus, which process comprises culturing cells infected with the virus in an aqueous culture medium in which the concentration of sodium chloride is from 30 mM to 170 mM above the isotonic concentration of sodi... | 04/09/1996 |
| 5476658 | Vaccine against hepatitis a comprising simian HAV isolate AGM-27 The present invention relates, in general, to a substantially pure preparation of the simian hepatitis A viral isolate AGM-27; a substantially pure preparation of the genomic DNA of simian hepatitis A viral isolate AGM-27; a pharmaceutical composition com... | 12/19/1995 |
| 5151023 | Hepatitis A,B-combined adjuvanted vaccine A hepatitis A, B-combined adjuvanted vaccine is disclosed in this application, said vaccine comprising an inactivated hepatitis A virus antigen, a hepatitis B virus surface antigen and an adjuvant. The present vaccine is obtained by causing the antigens t... | 09/29/1992 |
| 5100662 | Steroidal liposomes exhibiting enhanced stability The present invention relates to novel liposomes and liposome-like structures (vesicles) comprising an amount of a derivatized sterol either alone or in combination with additional liposome-forming lipids. Sterols such as cholesterol or other lipids, to which ... | 03/31/1992 |
| 5021348 | Attenuated hepatitis A virus Hepatitis A virus is attenuated by propagation in cell culture in vitro by direct inoculation of the cell cultures with a human clinical specimen containing the virus.... | 06/04/1991 |
| 4946676 | Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic, sequentially homologous peptide The invention relates to a new vaccine comprising a native protein capable of inducing the production of protective antibodies in a host, together with an adjuvant amount of certain proteins or peptides which, as such, are not capable of inducing substant... | 08/07/1990 |
| 4894228 | Vaccine against hepatitis A virus The present invention provides an attenuated hepatitis A virus useful as a vaccine.... | 01/16/1990 |
| 4783407 | Growth of hepatitus A virus in vero cells Hepatitus A virus is grown in Vero cells after passage in in vitro cell culture. Virus replication and continued passage in Vero cells requires extended incubation times, up to about four weeks, for early passages and incubation temperatures no higher tha... | 11/08/1988 |
| 4636469 | Isolation of hepatitis A virus strain HM-175 Human hepatitis A virus (HAV), taken directly from human clinical specimens, can be isolated and serially passaged in primary African green monkey kidney (AGMK) cell cultures. This strain induced antibody to HAV in inoculated chimpanzees and is useful for... | 01/13/1987 |
| 4620978 | Hepatitis A virus purified and triply cloned Human hepatitis A virus (HAV) can be purified by a process in which master seed lots of HM-175 strain of hepatitis A virus are prepared from triply cloned virus by terminal dilution at passage level about 20 or preferably at least 20-30. The clones tested... | 11/04/1986 |
| 4506016 | Hepatitis-A viruses adapted to human fibroblast cells Hepatitis-A virus, suitable for use in human or animal vaccines, is prepared by adapting the virus first to human kidney cells and subsequently adapting the thus-altered virus to human fibroblast strains. In the process the growth rate of Hepatitis-A viru... | 03/19/1985 |
| 4412002 | Process for preparing hepatitis A virus Hepatitis A virus is harvested from persistently infected cells, the cells are then trypsinized, replanted and a second harvest of hepatitis A virus is obtained. The cells can be trypsinized and replanted and harvested indefinitely.... | 10/25/1983 |
| 4391796 | Hepatitis B testing and growth in tree shrew as animal model Tree shrews (Tupaia belangeri) are used as an animal model to test the inactivation of vaccines, the harmlessness of blood products and the effectiveness of chemotherapeutic agents and disinfectants against viral hepatitis. The antibody determinations are... | 07/05/1983 |
| 4355019 | Hepatitis A testing and growth in tree shrew as animal model Tree shrews (Tupaia belangeri) are used as an animal model to test the inactivation of vaccines, the harmlessness of blood products and the effectiveness of chemotherapeutic agents and disinfectants against viral hepatitis. The antibody determinations are... | 10/19/1982 |
| 4301249 | High titer production of hepatitis A virus Hepatitis A virus (HAV) is produced in high titer from tissue cultures grown on a hollow fiber capillary unit.... | 11/17/1981 |
| 4164566 | Hepatitis a virus cell culture in vitro Hepatitis A virus is passaged at least once in a susceptible sub-human primate; the infected liver from such passage is used to inoculate an in vitro cell culture, the inoculated cell culture is incubated until hepatitis A antigen is detected in the cell ... | 08/14/1979 |
| 4031203 | Hepatitis A antigen Hepatitis A antigen obtained from the livers of non-human primates infected with hepatitis A (infectious hepatitis) virus has been found to be usable in fast, simple assays for hepatitis A antibody and thus usable in diagnosis of hepatitis A disease in hu... | 06/21/1977 |
| 4029764 | Hepatitis A antigen Hepatitis A antigen obtained from the livers of non-human primates infected with hepatitis A (infectious hepatitis) virus has been found to be usable in fast, simple assays for hepatitis A antibody and thus usable in diagnosis of hepatitis A disease in hu... | 06/14/1977 |
| 4017601 | Hepatitis A antigen Hepatitis A antigen obtained from the stools of patients infected with hepatitis A (infectious hepatitis) virus has been found to be usable in fast, simple assays for hepatitis A antibody and thus usable in diagnosis of hepatitis A disease, and for the pr... | 04/12/1977 |
